Roche Diabetes Care recalled its Accu-Chek Connect diabetes management app over software issues, according to an FDA safety alert issued Feb. 15.

Roche Holding AG plans to test whether an experimental medicine can prevent Alzheimer’s disease symptoms in high-risk people, its latest investment in one of the most failure-prone areas of ...

Stephen Ranjan believes teamwork is just as crucial as technology in building successful digital healthcare solutions in the pharma space ...

Roche’s Elecsys pTau181 test has secured CE Mark approval, marking a development in ruling out Alzheimer's disease. The minimally invasive blood test measures phosphorylated Tau (pTau) 181 ...

Roche will advance an experimental Parkinson’s disease drug with a mixed track record into late-stage development, announcing Monday that it is “encouraged by the efficacy signals” the ...

Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors.

The $7.1 billion deal will give Roche rights to develop and commercialize RVT-3101 as a therapy for inflammatory bowel disease.

Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs ...